Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

871 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN, Duan MH, Zhou H, Xu N, Zhang SJ, Zuo XL, Du X, Wang L, Li P, Zhang XH, Wu DX, Li YN, Zhang JJ, Wang W, Shen WH, Zagrijtschuk O, Sato T, Xiao ZJ, Jin J. Suo SS, et al. Among authors: chen sn. J Hematol. 2024 Apr;13(1-2):12-22. doi: 10.14740/jh1245. Epub 2024 Apr 9. J Hematol. 2024. PMID: 38644985 Free PMC article.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
Ma YF, Lu Y, Wu Q, Lou YJ, Yang M, Xu JY, Sun CH, Mao LP, Xu GX, Li L, Huang J, Wang HY, Lou LJ, Meng HT, Qian JJ, Yu WJ, Wei JY, Li ZY, Zhu XL, Yan XY, Chen SN, Jin J, Zhu HH. Ma YF, et al. Among authors: chen sn. J Hematol Oncol. 2022 Oct 18;15(1):148. doi: 10.1186/s13045-022-01368-3. J Hematol Oncol. 2022. PMID: 36258250 Free PMC article.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2022 Oct 31;15(1):159. doi: 10.1186/s13045-022-01369-2. J Hematol Oncol. 2022. PMID: 36316695 Free PMC article. No abstract available.
A global study for acute myeloid leukemia with RARG rearrangement.
Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Mi YC, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. Zhu HH, et al. Among authors: chen sn. Blood Adv. 2023 Jul 11;7(13):2972-2982. doi: 10.1182/bloodadvances.2022008364. Blood Adv. 2023. PMID: 36799929 Free PMC article.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2023 Feb 20;16(1):13. doi: 10.1186/s13045-023-01414-8. J Hematol Oncol. 2023. PMID: 36803531 Free PMC article. Clinical Trial. No abstract available.
871 results